First-dose idarubicin cardiomyopathy: A case of new heart failure after induction chemotherapy for acute myeloid leukaemia

Zarir Ahmed; Elizabeth Davaro; Jacqueline Batanian; Nilesh Verma

doi:10.1136/bcr-2018-228149

First-dose idarubicin cardiomyopathy: A case of new heart failure after induction chemotherapy for acute myeloid leukaemia

Zarir Ahmed, Elizabeth Davaro, Jacqueline Batanian, Nilesh Verma

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Anthracyclines are an effective chemotherapy agent. However, very few cases of idarubicin-induced cardiomyopathy exist. Herein, we describe a case of first-dose idarubicin-related acute heart failure in a woman with a history of myelodysplastic syndrome converted to acute myeloid leukaemia.

Original language	English (US)
Article number	e228149
Journal	BMJ Case Reports
Volume	12
Issue number	5
DOIs	https://doi.org/10.1136/bcr-2018-228149
State	Published - May 16 2019
Externally published	Yes

Keywords

cardiovascular system
chemotherapy
haematology (incl blood transfusion)
heart failure

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1136/bcr-2018-228149

Cite this

@article{73b85a839617488083ba360cc6889115,

title = "First-dose idarubicin cardiomyopathy: A case of new heart failure after induction chemotherapy for acute myeloid leukaemia",

abstract = "Anthracyclines are an effective chemotherapy agent. However, very few cases of idarubicin-induced cardiomyopathy exist. Herein, we describe a case of first-dose idarubicin-related acute heart failure in a woman with a history of myelodysplastic syndrome converted to acute myeloid leukaemia.",

keywords = "cardiovascular system, chemotherapy, haematology (incl blood transfusion), heart failure",

author = "Zarir Ahmed and Elizabeth Davaro and Jacqueline Batanian and Nilesh Verma",

note = "Publisher Copyright: {\textcopyright} BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2019",

month = may,

day = "16",

doi = "10.1136/bcr-2018-228149",

language = "English (US)",

volume = "12",

journal = "BMJ Case Reports",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

number = "5",

}

TY - JOUR

T1 - First-dose idarubicin cardiomyopathy

T2 - A case of new heart failure after induction chemotherapy for acute myeloid leukaemia

AU - Ahmed, Zarir

AU - Davaro, Elizabeth

AU - Batanian, Jacqueline

AU - Verma, Nilesh

N1 - Publisher Copyright: © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2019/5/16

Y1 - 2019/5/16

N2 - Anthracyclines are an effective chemotherapy agent. However, very few cases of idarubicin-induced cardiomyopathy exist. Herein, we describe a case of first-dose idarubicin-related acute heart failure in a woman with a history of myelodysplastic syndrome converted to acute myeloid leukaemia.

AB - Anthracyclines are an effective chemotherapy agent. However, very few cases of idarubicin-induced cardiomyopathy exist. Herein, we describe a case of first-dose idarubicin-related acute heart failure in a woman with a history of myelodysplastic syndrome converted to acute myeloid leukaemia.

KW - cardiovascular system

KW - chemotherapy

KW - haematology (incl blood transfusion)

KW - heart failure

UR - http://www.scopus.com/inward/record.url?scp=85065895337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065895337&partnerID=8YFLogxK

U2 - 10.1136/bcr-2018-228149

DO - 10.1136/bcr-2018-228149

M3 - Article

C2 - 31101747

AN - SCOPUS:85065895337

SN - 1757-790X

VL - 12

JO - BMJ Case Reports

JF - BMJ Case Reports

IS - 5

M1 - e228149

ER -

First-dose idarubicin cardiomyopathy: A case of new heart failure after induction chemotherapy for acute myeloid leukaemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this